Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2우한 균주에서 Omicron B.1.1.529까지의 SARS-CoV-2 수용체 결합 도메인은 인간 ACE2의 가변 구조에 대한 증가된 친화성을 특성으로 합니다.Article Published on 2022-07-012022-09-11 Journal: Journal of infection and public health [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] ACE2 ACE2 receptor ACE2 receptors ACE2 variant ACE2 variants ACE2-RBD affinity analysed Analysis angiotensin Angiotensin-converting enzyme attribute B.1.1.529 binding binding domain binding efficiency binding energy Care caused changes in coding region complexes contributing to COVID-19 detect determine docking dynamic Dynamic simulation enzyme Genetic variant genetic variants global pandemic help highlight homology model Homology models Human human ACE2 human host Infectious disease Interaction isolates lead management molecular molecular dynamics nucleotide omicron pathogenic polymorphism Protein docking RBD RBD complex RBDs receptor Receptor binding domain Repository retrieved risk RMSD RMSF Safe SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 genomes SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 virus SARS‐CoV‐2 selected severity single nucleotide stability Structural variant structural variants Structure the RBD Total variant Variation was performed wildtype Wuhan Wuhan strain [DOI] 10.1016/j.jiph.2022.06.004 PMC 바로가기 [Article Type] Article
COVID-19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2COVID-19: 오미크론 - 최신, 가장 덜 독성이지만 SARS-CoV-2의 우려의 마지막 변종은 아닐 것입니다.Review Published on 2022-07-012022-09-11 Journal: Microbial Biotechnology [Category] COVID19(2023년), SARS, 변종, [키워드] affected Antibody Response Antiviral booster breadth cell entry Cellular immune response convalescent patient Convalescent patients COVID-19 pandemic Delta demonstrated dominant Endocytic pathway experiment explain fusion hamsters Immune escape immunization Infection intrinsic less Lineage Lung function mainstream mice monoclonal antibodies mutated Mutation neutralization omicron Omicron variant plasma membrane population immunity preserved question raising Replication respiratory tract SARS-CoV-2 SARS-CoV-2 strain serum antibodies serum antibody Severe infection severe infections South Africa Spike protein the spike protein therapeutic titre trajectory Transmission vaccinee vaccinees variant virulence virulent VoC widespread [DOI] 10.1111/1751-7915.14064 PMC 바로가기 [Article Type] Review
COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort studySARS-CoV-2의 B.1.1.7(알파) 변이와 비교한 B.1.617.2(델타) 변이로 인한 COVID-19: 전향적 관찰 코호트 연구Observational Study Published on 2022-06-282022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 임상, 진단, [키워드] 1:1 age Alpha B.1.1.7 B.1.617.2 circulating comparison COVID COVID-19 Delta delta variant disease Dyspnoea Effectiveness Efficacy Fever headache hospital hospitalisation illness illness duration individual individuals Infection positive predominant presenting prospective observational cohort Re-infections reduced regions Reinfection Research risk SARS-CoV-2 SARS-CoV-2 strain Seven sore throat Symptom symptom burden symptomatic adult symptomatic adults Symptoms tested Transmission Vaccine variant variants were assessed [DOI] 10.1038/s41598-022-14016-0 PMC 바로가기 [Article Type] Observational Study
Genome sequence diversity of SARS-CoV-2 obtained from clinical samples in Uzbekistan우즈베키스탄의 임상 샘플에서 얻은 SARS-CoV-2의 게놈 서열 다양성Article Published on 2022-06-272022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected Alpha Amino acid amino acid substitution annotation association change clade clades clinical isolates clinical sample Cluster coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 severity D614G Deleterious Deletion Delta Denmark disease severity evidenced Evolution female followed by genetic diversity Genome Genomic analysis genomic change Genotype help Identified isolate isolates male Missense Missense mutation Missense mutations Mutation Nextstrain NSP Nsp12 nsp13 Nsp3 nsp4 NSP6 nucleotide Open reading frame ORF ORF7a Pathogenesis PCR-positive patient Protein reading regions Research Russia SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants sequence severe acute respiratory syndrome Coronavirus severity significantly SNP SNPs subclade Substitution synonymous Tashkent the Spike two group two groups USA variant variants Variation WGS whole genome sequence with COVID-19 [DOI] 10.1371/journal.pone.0270314 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial무작위 2상 시험에서 BBIBP-CorV 수용자에서 하이브리드형 백신 부스터의 안전성 및 면역원성Clinical Trial Published on 2022-06-272022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] 1:1 Administered Adverse reaction Adverse reactions age Antigen antigens BBIBP-CorV boost booster booster dose conducted dose double-blind elicited evaluate GMT greater group healthy Heterologous homologous IgG antibodies IgG antibody immunogenic immunogenicity incidence Neutralizing and IgG antibodies neutralizing antibody omicron Omicron variant participant Phase 2 phase 2 trial Randomized receive recipient recombinant COVID-19 vaccine regimens Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 strain significantly higher three groups United Arab Emirate United Arab Emirates Vaccine variant variants of concern VOCs [DOI] 10.1038/s41467-022-31379-0 PMC 바로가기 [Article Type] Clinical Trial
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history백신 접종 및 감염 이력에 의한 SARS-CoV-2 Delta 및 Omicron 변이체에 대한 반응성 중화Article Published on 2022-06-102022-09-11 Journal: Genome Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Abbott anti-S antibody antibody antibody persistence Antibody Response Antibody titre antibody titres Antigen B.1 B.1.1.529 B.1.617.2 blood sample Blood samples Cohort collected control group control groups controls COVID-19 cross-protective Delta delta variant DiaSorin dose elicited followed by generate group healthcare healthcare worker Immune escape Immunity immunoassays increasingly individuals induce Infection investigated N antigen naïve naïve subject naïve subjects natural infection neutralisation neutralising Neutralising Antibodies nucleocapsid omicron Omicron variant performed persistence Post-infection presence of antibody question reactivity required Roche S antigen SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants sera Serosurvey serum significantly subject subjects tested the SARS-CoV-2 timepoints two groups vaccinated individuals vaccination Vaccine Vaccine development variant virus VoC VOCs weakened were used while [DOI] 10.1186/s13073-022-01066-2 PMC 바로가기 [Article Type] Article
Computational study and design of effective siRNAs to silence structural proteins associated genes of Indian SARS-CoV-2 strains인도 SARS-CoV-2 균주의 구조 단백질 관련 유전자를 침묵시키는 효과적인 siRNA의 계산 연구 및 설계Article Published on 2022-06-012022-09-11 Journal: Computational biology and chemistry [Category] COVID19(2023년), SARS, 치료법, 치료제, [키워드] absence acute respiratory disease Ago2 Algorithm animal models antiviral drug antiviral drugs Antiviral treatment binding candidate collected complementary Consensus COVID-19 deaths docking Effect effective envelope protein feature free energy GC content gene silencing Genes Genome Health Organization heat capacity Human Human genome in vitro in vivo India melting temperature membrane protein molecular docking analysis nucleic acid nucleocapsid nucleotide nucleotides outbreak pandemic parameter pathogenic coronavirus pathway Post-transcriptional gene silencing Protein public health Region reported Respiratory disease RNA RNA interference RNAi SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 strains selected sequence sequenced siRNA siRNA molecule siRNA molecules siRNAs structural protein structural proteins Surface glycoprotein target target gene target mRNA temperature Therapeutic treatment triggered viral pathogenesis WHO World Health Organization [DOI] 10.1016/j.compbiolchem.2022.107687 PMC 바로가기 [Article Type] Article
Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern우려되는 신종 SARS-CoV-2 변이체에 대한 BIV1-CovIran 비활성화 백신 유도 중화 항체 평가Article Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Alpha antibody assessment B.1.1.7 B.1.351 B.1.617.2 Beta binding domain BIV1-CovIran vaccine candidate vaccine conventional virus neutralization test correlated correlation COVID-19 COVID-19 vaccine Delta delta variant Delta variants demonstrated effective exhibited inactivated individual investigated NAb NAbs neutralization neutralization test neutralize Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody Protein recipient recipients reduction in SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants sensitivity sera serum Spearman the SARS-CoV-2 titre Vaccine vaccinee vaccinees variant variants variants of concern virus neutralization test virus-neutralizing was measured Wuhan strain [DOI] 10.1016/j.cmi.2022.02.030 PMC 바로가기 [Article Type] Article
Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19COVID-19에 대한 비강내 예방으로서 광범위한 변이 활성을 갖는 계란 유래 항-SARS-CoV-2 면역글로불린 Y(IgY)Clinical Trial Published on 2022-06-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 2019 novel coronavirus 2019-nCoV activity Administered Against Alpha anti-SARS-CoV-2 Antiviral approval approvals B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta binding capture chicken immunoglobulin clinical clinical trial clinical trial body Clinical use contagiousness Convalescent patients COVID-19 cross-reactivity Delta demonstrated develop Diseases distribution double-blind effective Emergency use authorization enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Evidence evidence of greater healthy human tissue human tissues IgY Immunity immunized Immunoglobulin immunoglobulin Y index Infectious diseases intranasal intranasally multiple dose multiple doses nasal drop nasal drops nasal mucosa neutralization titer no evidence of Novel coronavirus omicron Phase 1 phase 1 study Placebo placebo-controlled Prevalence Prophylaxis raised Randomized RATs RBD Receptor-binding domain reduce reduced risk Safe safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 viral sensitivity sera Spike protein the receptor-binding domain the SARS-CoV-2 Tolerability Transmission Trial Vaccine Vaccine hesitancy variants variants of concern variety Viral virus [DOI] 10.3389/fimmu.2022.899617 PMC 바로가기 [Article Type] Clinical Trial
Genomic profiles of vaccine breakthrough SARS-CoV-2 strains from Odisha, India인도 오디샤(Odisha)의 백신 혁신 SARS-CoV-2 균주의 게놈 프로필Article Published on 2022-06-012022-09-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] Abstract concern COVID-19 India profile SARS-CoV-2 SARS-CoV-2 strain Vaccine Vaccine breakthrough variants variants of concern [DOI] 10.1016/j.ijid.2022.03.042 PMC 바로가기 [Article Type] Article